Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $32 from $26 and keeps a Sell rating on the shares. The firm updated the company’s model to reflect the Novartis collaboration, which it notes boosts PTC’s liquidity position to $2B. The PTC518 collaboration “brings big pharma muscle and big cash upfront,” the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $71 from $47 at UBS
- PTC Therapeutics price target raised to $70 from $52 at Baird
- PTC Therapeutics price target raised to $41 from $31 at BofA
- PTC Therapeutics price target raised to $56 from $45 at Barclays
- PTC Therapeutics’ Novartis deal expedites value creation, says Wells Fargo